

COVAX ALLOCATION ROUND 5/Q3 Available Supply

Date of report: 6 July 2021

Summary

- COVAX Allocation Round 5 concerns the allocation of COVAX Facility secured supplies of **Pfizer BioNTech - Comirnaty** ("Pfizer")¹ for the period of **July to September 2021 (Q3-2021)**. The available supply of Pfizer in this Round includes 12,190,230 doses secured through the COVAX Facility advance purchase agreement with the manufacturer. An additional 59,999,940 doses are made available to the COVAX Facility for Q3-2021 allocation to the entire group of AMC participants as well as six SFPs in the African Union, through a procurement facilitated by the government of the United States of America (USG).
- This allocation Round takes into account the coverage achieved by each participant thanks to the donations done through COVAX since Round 4. These donations will be delivered during Q3. They are listed below:
 - The government of the **United States of America** (USG) confirmed a **donation of 59,899,940 doses** available for distribution beginning in June 2021. This donation comprised a total of:
 - 16,333,200 doses of Pfizer vaccine;
 - 25,650,340 doses of Moderna - mRNA-1273 ("**Moderna**"); and
 - 17,906,400 doses of Janssen - Ad26.COV 2-S ("**Janssen**").It is part of a wider USG dose donation initiative. The total population coverage achieved in benefitting participants is accounted for as an input going into COVAX Allocation Round 5. At the time of writing of this report, some of the donation details are still under discussion, therefore some adjustments to the donated doses per each beneficiary may be made in the future.
 - The government of **Japan** (JP) confirmed a donation of doses available in July 2021. This **donation consists of 11,239,200 doses of AstraZeneca/AZD1222-Vaxzevria** ("AZ") vaccine. The total population coverage achieved in benefitting participants is accounted for as an input going into COVAX Allocation Round 5. As the final details of this donation are still being discussed at the time of writing this proposal, small adjustments to the quantities per each beneficiary of this donation may be expected in the future.

¹ International Nonproprietary Name (INN): Pfizer BNT162b2/COMIRNATY Tozinameran.

- Supply needs for the **COVAX Humanitarian Buffer (HB)** are not factored into this allocation. The 5% of doses which would normally be allocated to the Humanitarian Buffer will be made up in future allocation rounds.
- Consequently, at the moment of writing of this report, overall doses available to COVAX in Q3 (thanks to donations and contractual agreements with manufacturers) amount to a total of 143,3 million of doses.
- **The overall quantity of Pfizer² to be distributed in this round is 72,190,170 doses to a total of 99 participants for the period July to September 2021.**
- **The average proportion of population coverage achieved across participants included in this Round is 1.7%. The average cumulative coverage from Rounds 1 to 5 for these same participants is 6.66%.**

Table of Contents

Summary.....	1
Table of Contents	2
Purpose.....	2
Background.....	3
Overview of Allocations to Date.....	3
Context for the Current Allocation Round.....	4
Scope	6
Vaccine Scope	6
Participant Scope	7
Allocation Objectives and Principles	9
Distribution Proposal.....	10
Others – Shipment Considerations.....	10
Conclusions.....	11
Signatures	11
ANNEX 1. Allocation Round 5 Results.....	12
ANNEX 2. Past Allocations	19

Purpose

The purpose of this document is to provide supportive data and a data-driven proposal for the allocation of COVAX Facility-secured supplies of **72,190,170 doses of Pfizer BioNTech - Comirnaty** (“Pfizer”)³ vaccine to eligible COVAX Facility participants for the period spanning from July through September 2021 (Q3-2021).

² This volume does not take into account the doses set aside for the Humanitarian Buffer.

³ International Nonproprietary Name (INN): Pfizer BNT162b2/COMIRNATY Tozinameran.

This allocation arrives on top of the donation of a total of 71.1M doses (59.9 million doses from the USG of J&J, Moderna and Pfizer as well as 11.2M AZ from Japan) for the same period (Q3).

This report serves to facilitate decision-making by the Independent Allocation of Vaccines Group ([IAVG](#)).

Background

This section provides an overview of the allocations made by the COVAX Facility to date along with a description of pertinent issues that may affect allocation decision-making specific to the current Round (Round 5).

Overview of Allocations to Date

To date, four Allocation Rounds have taken place:

- The first three Allocation Rounds cover the period from January through June of 2021 (Q1-2021 & Q2-2021) and involved **AstraZeneca/AZD1222-Vaxzevria**⁴ (“AZ”), **AstraZeneca/Covishield**TM (“SII”) and **Pfizer** vaccines.
- The fourth Allocation Round took place prior to this current one (on 8 June 2021). [Round 4](#) consisted of an exceptional allocation to cover the second dose needs of COVAX Facility participants affected by the sudden global disruption of SII supplies from the Serum Institute of India following [Round 2](#)⁵ and to service a small number of participants who had not received any shipment of Round 2 SII doses due to preparedness and/or supply issues.

In advance of Round 5, **Pfizer** vaccine allocations included the following:

- A total of **15,309,450** doses were allocated as a result of COVAX Allocation Rounds 1 and 3 covering the period January-June 2021. Out of this total, 12,795,120 doses have been shipped to 41 participants.⁶
- A total of **16,333,200** doses were allocated as part of the USG dose donation. For Round 5, the total population coverage achieved among the beneficiaries of this donation is accounted for as an input. Volumes from this donation will be delivered to participants during the same period covered by this allocation round.

To date, four other vaccine products have been allocated through the COVAX Facility:

- **AZ**: a total of **92,779,200 doses**⁷ were allocated as a result of [COVAX Allocation Round 2](#) and [Round 4](#). Out of this total, 49,729,200 doses have been shipped to 89 participants.⁸ The fourth Allocation Round resulted in the allocation of 17,366,400 AZ doses to 43 participants chiefly to

⁴ Previously COVID-19 Vaccine AstraZeneca.

⁵ <https://www.gavi.org/news/media-room/covax-updates-participants-delivery-delays-vaccines-serum-institute-india-sii-az>

⁶ Shipment data as of 07 July 2021 as reported on the UNICEF COVAX Procurement Portal.

⁷ Accounting for the supply reduction affecting Round 2 allocations.

⁸ Shipment data as of 07 July 2021 as reported on the UNICEF COVAX Procurement Portal.

cover second dose needs as mentioned above. An additional 13,152,000 doses were allocated to some participants benefitting from dose donations through the COVAX Facility.⁹

- **SII:** a total of **161,472,000 doses** were allocated as a result of [COVAX Allocation Round 2](#) to 60 participants. However, the post-allocation delivery of these doses was disrupted beginning in March and April 2021 such that only 29,790,600 of these doses were delivered to 50 participants¹⁰ (see Context for the Current Allocation Round below).
- **Moderna** (through dose donation only): a total of **25,650,340** doses were donated as part of the USG dose donation described in more details in the following section of this report. For Round 5, the total population coverage achieved among the beneficiaries of this donation is accounted for as an input. Volumes from this donation will be delivered to participants during the same period covered by this allocation round.
- **Janssen** (through dose donation only): a total of **17,906,400** doses were donated as part of the USG dose donation described in more details in the following section of this report. For Round 5, the total population coverage achieved by beneficiaries of this donation is accounted for as an input. Volumes from this donation will be delivered to participants during the same period covered by this allocation round.

Please refer to Table 1 in ANNEX 2 for an overview of all allocations preceding Round 5.

Context for the Current Allocation Round

The SII supply shortage, the equivalence of AZ and SII vaccines, and Allocation Round 4

Due to a surge in COVID-19 infections in the country, the Government of India halted the export of vaccines produced by the Serum Institute of India, therefore interrupting the supply of SII doses to the COVAX Facility beginning in March 2021.¹¹

In [COVAX Allocation Round 2](#), 161,472,000 SII doses had been allocated to 60 AMC participants for the period January to May 2021. In the period preceding the halt in the export of vaccines produced by the Serum Institute of India, only a small proportion of allocated SII doses had been delivered as first tranche shipments to participants, the majority of whom reported having used them primarily as first doses to target high risk populations in accordance with WHO recommendations on [Considerations for optimizing deployment of ChAdOx1-S \[recombinant\] vaccines in a time-limited constrained supply situation](#).

As the Allocation Framework aims to allocate full courses, in this case constituting a two-dose regimen, this development necessitated running an additional allocation round (i.e. [COVAX Allocation Round 4](#)) to address second dose needs. As a result, Round 4 was run primarily to cover the second dose needs of COVAX participants previously allocated SII who used the majority or entirety of their first shipment as first doses. The Round 4 supply did not include any SII doses.

⁹ These include donations from France (for a cumulative total of 1,701,600 doses earmarked to 14 participants in the WHO AFR region), a donation from New Zealand (211,200 doses earmarked to 6 participants in the WHO WPR & SEAR regions), a donation from Japan (11,239,200 doses earmarked to 15 participants in the WHO EMR, SEAR and WPR regions).

¹⁰ Shipment data as of 07 July 2021 as reported on the UNICEF COVAX Procurement Portal.

¹¹ <https://www.gavi.org/news/media-room/covax-updates-participants-delivery-delays-vaccines-serum-institute-india-sii-az>

This was made possible given the equivalence of AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield to ChAdOx1-S, as these products are interchangeable.¹² The WHO recommends that both doses should be administered with ChAdOx1-S products. Studies are underway to assess whether COVID-19 vaccines using a different platform can be used interchangeably in the dosing schedule. WHO recommendations may be updated as further information becomes available. More information can be accessed [here](#).

Round 5 Scope: Limited to Pfizer Vaccine Only

Since [COVAX Allocation Round 3](#) in March 2021, several vaccines have received WHO Emergency Use Listing (EUL), including: Moderna COVID-19 vaccine (mRNA-1273); Janssen - Ad26.COV 2-S (also known as Johnson & Johnson); Beijing CNBG - BBIBP-CorV (also known as Sinopharm); and Sinovac – CoronaVac. An overview of the status of COVID-19 vaccines in the WHO EUL/PQ evaluation process is available [here](#).

Furthermore, the COVAX Facility has entered into supply agreements with eight manufacturers,¹³ including Janssen (also known as Johnson & Johnson) and Moderna. Whilst some quantities of these vaccines were made available through donations from donor governments to the COVAX Facility, there has not yet been provided confirmation of available supply from these manufacturers for COVAX in this quarter. Therefore, no quantities of these vaccines are considered for allocation in this Round.

Additional Allocation Rounds will be announced, including for the period July to September 2021, as and when supply availability from these or any other manufacturers is confirmed. The latest COVAX Global Supply Forecast may be accessed [here](#).

Vaccine Donations to COVAX

Allocation Round 5 also builds upon the coverage achieved by means of donations of vaccines to COVAX. The Facility is experiencing a significant increase in **dose donations** from donor governments. To date, donations from France,¹⁴ New Zealand,¹⁵ and most recently the United States of America¹⁶ and Japan have been allocated to participants. Additional donations from Sweden¹⁷ have been announced and others are under discussion.

Whilst the allocation of these doses to COVAX participants has so far been managed outside of the formal allocation mechanism (due either to a limited number of doses donated or to beneficiary earmarking by the donor), the increase in the percent total population coverage achieved through COVAX-secured doses as a result of these donations is factored into this Allocation Round. All the donations to COVAX have been accounted for in participants' total COVAX coverage levels ahead of running Round 5, including the latest donations from the United States of America and from Japan. However, adjustments can be foreseen due to negotiations with these donors still being finalized. The JAT highlights that two participants benefitting from these donations achieve a population coverage above 100%. These two participants are not included in this allocation round for this reason and will require a revision in allocated doses.

¹² https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1

¹³ <https://www.gavi.org/news/media-room/gavi-signs-agreement-johnson-johnson-supply-its-covid-19-vaccine-covax>

¹⁴ <https://www.gavi.org/news/media-room/france-makes-important-vaccine-dose-donation-covax>

¹⁵ <https://www.gavi.org/news/media-room/new-zealand-transfers-vaccine-doses-covax-6-pacific-nations-first-benefit>

¹⁶ <https://www.whitehouse.gov/briefing-room/statements-releases/2021/06/03/fact-sheet-biden-harris-administration-unveils-strategy-for-global-vaccine-sharing-announcing-allocation-plan-for-the-first-25-million-doses-to-be-shared-globally/>

¹⁷ <https://www.government.se/press-releases/2021/05/ny-the-government-plans-to-donate-one-million-vaccine-doses-to-the-covax-global-vaccine-cooperation/>

Please refer to Table 1 in ANNEX 2 for an overview of all donations preceding Round 5.

Scope

Vaccine Scope

In terms of vaccines, the scope of the current allocation proposal is limited to the Q3-2021 supply of Pfizer vaccine secured through the COVAX Facility (see the rationale above).

Information on supply availability was provided to the Joint Allocation Taskforce by the COVAX Procurement Coordinator, UNICEF Supply Division.

Additionally, the USG has been facilitating the procurement of an additional 59,999,940 Pfizer doses for the COVAX Facility for delivery in Q3-2021. These doses are included in this Allocation Round and are earmarked specifically to the entire group of AMC participants, as well as to six SFPs who are members of the African Union.¹⁸

Allocation of Doses to the COVAX Humanitarian Buffer

Supply needs for the Humanitarian Buffer are not factored into this Pfizer vaccine allocation round, as the operational and logistical complexities related to this product pose significant challenges to its swift distribution in humanitarian settings for the time being, potentially leading to idle doses. The decision was taken in agreement with the IASC DG but may be reviewed in future allocation rounds. The 5% of doses which would normally be allocated to the Humanitarian Buffer will be made up in future allocation rounds.

Table 1 below provides the minimum shipment size for Pfizer vaccine. The final supply quantity to be allocated in Round 5, considering monthly production forecasts, is included in Table 2.

Table 1. Minimum Shipment Size per Product

Product Name	Minimum shipment size (doses)
Pfizer BioNTech – Comirnaty	1,170

Table 2. Overview of Pfizer Available Supply for Round 5

Vaccines supply for Round 5	TOTAL
Pfizer BioNTech – Comirnaty	12,190,230
Pfizer BioNTech – Comirnaty (through a procurement facilitated by USG)	59,999,940

¹⁸ The six AU SFPs eligible to be allocated the Pfizer doses available through a procurement facilitated by USG are : Botswana, Gabon, Libya, Mauritius, Namibia, and South Africa.

Participant Scope

COVAX Facility Participants

There are 89 Advance Market Commitment (AMC) and 73 Self Financing¹⁹ (SFP) participants to the COVAX Facility.

Readiness Assessment

Before being included in the Allocation Round, AMC participant readiness assessments are regularly conducted. Participants used and submitted readiness data through the Vaccine Introduction and Readiness Assessment Tool (VIRAT). At the same time, National Deployment and Vaccination Plans (NDVPs) were prepared and submitted by all participants, and a multi-disciplinary, multiagency (WHO, UNICEF, Gavi) review of the plans took place. Exceptionally, given the need to expand access to vaccines across all COVAX participants and the amount of vaccine doses available for this round, the COVAX Facility decided to include all AMC participants in this round, accepting that some of them may not be in a position to manage and absorb this vaccine. Such issues will be managed through reallocation of doses, a standard and formalized process that takes place after the communication of validated allocations to countries and which is conducted in consultation with several partners, including regional and country offices. All COVAX Partners will strive to support participants that may have challenges in managing this vaccine, to ensure effective use of the allocated doses.

Eligibility Criteria for Pfizer Recipients

Considering specific requirements related to the Pfizer product and to the earmarking of the doses of which the procurement was facilitated by the USG, the following participants were eligible to receive available supplies of Pfizer vaccine in this Allocation Round:

- All AMC participants
- Optional Purchaser (OPs) who opted-in for the Pfizer vaccine deal
- Committed Purchasers (CPs) without price cap

Delay Toggle and Vaccines Characteristics Preferences

Between Allocation Rounds 3 and 5, the COVAX Facility launched the COVAX Collaboration Platform (CCP),^{20,21} through which participants are invited to:

- Rank and/or update their vaccine characteristic preferences,

¹⁹ Please note these numbers reflect latest information on COVAX Participants. Some of this information may not be reflected in publicly available documents yet.

²⁰ The COVAX Collaboration Portal (CCP) is the platform through which COVAX participants are able to access and modify information relating to their allocations and vaccine characteristic preferences, an activity which was initially executed through the Vaccine Request and Vaccine Information Forms submitted to the Facility before the first allocation round. In advance of each round, participants will be invited to update their vaccine characteristic preferences and choose whether to use the round delay toggle as an input into the allocation mechanism. The JAT will communicate further updates to the CCP as they are implemented.

²¹ COVAX Country Communications dispatched a letter to Facility participants on 21 May 2021, notifying participants of the scope and timing for the upcoming allocation round. In this same communication, participants were provided with additional guidance on updating vaccine characteristic preferences and skipping an allocation using the COVAX Collaboration Platform (CCP). Subsequently, two *Delivery and Supply Update* participant briefings were held on 28 and 31 May 2021, during which participants were informed of these changes. Participants are updated on CCP changes through communications as they are implemented.

- Decide on whether they wish to use the Round delay toggle²² before the algorithm is run for a given Allocation Round,
- Express whether, in the next and future Allocation Rounds, they would prefer to receive a new product which better aligns with their vaccine characteristic preferences or whether they would prefer to receive the same vaccine that was previously allocated to them.

Participant-provided data submitted through the CCP serve as inputs for Allocation Round 5 .

Exclusion of Participants

Allocation Round 5 will not include the following 63 COVAX Facility participants:

- Small-population participants who already reached 20% total population coverage through COVAX-secured vaccine doses and participants who have reached their requested population coverage,
- Committed Purchaser SFPs that had a price opt-out and Optional Purchaser SFPs who opt out of the Round,
- Participants who used the delay toggle to opt-out of the entire round,
- Optional Purchaser SFPs who have already achieved their total pro-rata share of Pfizer doses, in accordance with their participant model terms and conditions.

Table 3 on the following page summarizes the characteristics of the participants eligible to receive an allocation in Round 5.

²² The delay toggle allows participants to indicate via the CCP that they would like to skip the allocation and have their coverage caught up in future rounds. If and when using it, participants opt out of being allocated any product(s) in that round.

Table 3. Participants Eligible to Receive Pfizer

	Participants (n)
Inclusion	
Advanced Market Commitment (AMC)	89
Optional Purchasers (OP)	39
Committed Purchasers (CP)	31
Team Europe	3
Total Inclusion	162
Exclusion	
Financial obligation not met	• 1
Opt out	• 2 Committed Purchasers due to price • 18 Optional Purchasers
Delay toggle	4
Not ready	0
20% population reached and/or requested population reached	20
Deal fulfilled	16
Others not allowed combination ²³	2
Total Exclusion	63

Considering these supply and demand characteristics, the overall number of doses to be allocated during Round 5 is 72,190,170 doses of Pfizer vaccine to be distributed among 99 participants.

Allocation Objectives and Principles

The [Allocation Algorithm](#) strives for an optimized allocation according to three objectives for Phase 1:

1. Participants should receive doses such that they all progress at the same rate, achieving the same proportion of total population coverage over time^{24,25}
2. Participants should receive a single product throughout where possible^{26,27}
3. Participants receive products in line with their vaccine characteristic preferences where possible²⁸

²³ No allowed combination means that there is no deal in the round for which the participant is eligible to receive an allocation, for other purposes than the ones already detailed in the table.

²⁴ With exception for less populous participants due to logistics constraints.

²⁵ Apart from the Pfizer vaccine, which has specific characteristics, and which is not likely to be used to cover the full request for coverage through the COVAX Facility for any one participant.

²⁶ Apart from the Pfizer vaccine, which has specific characteristics, and which is not likely to be used to cover the full request for coverage through the COVAX Facility for any one participant.

²⁷ For AMC Participants and Committed Purchase SFP participants.

²⁸ Apart from the Pfizer vaccine, which has specific characteristics, and which is not likely to be used to cover the full request for coverage through the COVAX Facility for any one participant.

The algorithm aims to minimize inequality in terms of population coverage across participants over time. It is designed to identify the highest total coverage level it can achieve in as many participants as possible with the supply available in each Round. The equality is measured with an indicator called Equality Deviation: the lower the number, the higher equality achieved in the Round.

Once equality is achieved, the algorithm maximizes the product characteristic and the unique product preferences, aiming to allocate products to participants according to their preferences and consistent with the same products allocated in previous Rounds.

Distribution Proposal

The final list of Round 5 allocations is available in ANNEX 1, Table 1.

The average population coverage across all participants achieved with doses allocated in this round is **1.7%**. The average cumulative coverage from Rounds 1 to 5 for these same participants is **6.66%**.

A descriptive statistics summary of the participants, their allocation, and total coverage is presented in ANNEX 1, Table 2. A summary of the proposed distribution is presented in ANNEX 1, Figures 1-3.

Some participants receiving an allocation in Round 5 might face absorptive capacity constraints linked to logistics or to the fact that, having recently joined the COVAX Facility, the Round 5 allocation may constitute a high number of doses as the algorithm seeks to uphold its core principle of equality in coverage across participants.

Given the pending details relating to the finalization of dose donations taking place between Rounds 4 and 5 and relating to the finalization of the deal with Pfizer for the doses of which the procurement was facilitated by USG, adjustments may be made to the current allocation once all information is available. These adjustments will only aim to ensure that the achieved total population coverage through COVAX uphold the principles of [fair and equitable allocation](#) across all participants. Such changes, when needed, will be communicated to the IAVG for information and potentially for approval if such changes affect a significant proportion of the doses proposed for allocation in this present Vaccine Allocation Decision (VAD) proposal.

Others – Shipment Considerations

Normally, to facilitate logistics planning, a prioritized shipping order is recommended for distribution of doses allocated in a Round. In developing this order, a stratified randomization approach was adopted in past Rounds to ensure that all participants are given an equal chance in the initial shipment queue.

For Round 5, a decision was taken to inform the sequencing of shipments based on participants' overall achieved population coverage (from all sources of supply) and their epidemiological situation. Furthermore, it is recommended that, closer to the date of the planned shipment, participants' absorption capacity be assessed to ensure all the planned quantities can be used by participants within the vaccines' expiry dates. To prioritize the shipping order for the doses available in July, an additional criterion was applied to ensure that these immediately available doses can be absorbed. This was to prioritize Participants who had received Pfizer doses in Round 1 and/or Round 3, thereby ensuring that post-allocation preparedness steps involving regulatory approval and I&L have already been completed.

Conclusions

The JAT proposes the allocation amounts detailed in **ANNEX 1**. This proposal is to be validated by the IAVG. The JAT will provide any further data and needed details to assist the IAVG's final decision-making. IAVG members are encouraged to ask for further details (whether before or during the IAVG Decision Meeting) to enable the JAT to rapidly provide such information.

The following sequence of steps is envisaged to meet the key performance indicators:

Process Step	Date
JAT convenes the IAVG and sends allocation proposal	07 July 2021
IAVG Decision Meeting	08 July 2021
JAT notifies the Office of the COVAX Facility and the Procurement Coordinator	08 July 2021
IAVG report sent to the WHO DDG	08 July 2021
WHO DDG communicates to COVAX Facility	09 July 2021

Signatures

Signature Assistant Director General, Access to Medicines and Health Products, WHO	Signature Managing Director, Office of the COVAX Facility, Gavi
Mariângela SIMÃO	Aurélia NGUYEN
On date:	On date:

ANNEX 1. Allocation Round 5 Results

Table 1. List of Proposed Round 5 Allocations (N=99*)²⁹

Participant name	WHO region	COVAX Participation model	Doses allocated Pfizer BioNTech – Comirnaty
Afghanistan	EMR	AMC92	100,620
Algeria	AFR	AMC92	760,500
Andorra	EUR	OPTIONAL	2,340
Angola	AFR	AMC92	630,630
Azerbaijan	EUR	COMMITTED	100,620
Bahamas	AMR	COMMITTED	57,330
Bangladesh	SEAR	AMC92	6,020,820
Barbados	AMR	COMMITTED	14,040
Belize	AMR	COMMITTED	58,500
Benin	AFR	AMC92	332,280
Bolivia (Plurinational State of)	AMR	AMC92	100,620
Bosnia and Herzegovina	EUR	COMMITTED	100,620
Brazil	AMR	OPTIONAL	8,190
Burkina Faso	AFR	AMC92	1,107,990
Cambodia	WPR	AMC92	100,620
Cameroon	AFR	AMC92	861,120
Central African Republic	AFR	AMC92	100,620
Chad	AFR	AMC92	888,030
Colombia	AMR	COMMITTED	508,950
Congo	AFR	AMC92	331,110
Côte d'Ivoire	AFR	AMC92	629,460
Democratic Republic of the Congo	AFR	AMC92	4,696,380
Djibouti	EMR	AMC92	16,380
Dominican Republic	AMR	COMMITTED	107,640
Ecuador	AMR	COMMITTED	176,670
Egypt	EMR	AMC92	775,710
El Salvador	AMR	AMC92	100,620
Eswatini	AFR	AMC92	100,620
Ethiopia	AFR	AMC92	3,105,180
Gabon	AFR	COMMITTED	100,620
Gambia	AFR	AMC92	100,620
Ghana	AFR	AMC92	100,620

²⁹ The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Participant name	WHO region	COVAX Participation model	Doses allocated Pfizer BioNTech – Comirnaty
Guatemala	AMR	COMMITTED	169,650
Guinea	AFR	AMC92	402,480
Guinea-Bissau	AFR	AMC92	100,620
Guyana	AMR	AMC92	100,620
Haiti	AMR	AMC92	218,790
Honduras	AMR	AMC92	100,620
Indonesia	SEAR	AMC92	4,644,900
Iraq	EMR	COMMITTED	1,265,940
Israel	EUR	OPTIONAL	184,860
Jamaica	AMR	COMMITTED	100,620
Kenya	AFR	AMC92	271,440
Kosovo (in accordance with UN Security Council resolution 1244 (1999))	EUR	AMC92	18,720
Kyrgyzstan	EUR	AMC92	259,740
Lebanon	EMR	COMMITTED	100,620
Lesotho	AFR	AMC92	100,620
Liberia	AFR	AMC92	183,690
Madagascar	AFR	AMC92	1,478,880
Malawi	AFR	AMC92	372,060
Mali	AFR	AMC92	382,590
Mauritania	AFR	AMC92	104,130
Mauritius	AFR	COMMITTED	76,050
Monaco	EUR	OPTIONAL	1,170
Mongolia	WPR	AMC92	100,620
Montenegro	EUR	OPTIONAL	5,850
Morocco	EMR	AMC92	850,590
Mozambique	AFR	AMC92	1,226,160
Myanmar	SEAR	AMC92	4,048,200
Namibia	AFR	COMMITTED	100,620
Nepal	SEAR	AMC92	100,620
Nicaragua	AMR	AMC92	223,470
Niger	AFR	AMC92	859,950
Nigeria	AFR	AMC92	3,577,860
North Macedonia	EUR	COMMITTED	100,620
occupied Palestinian territory, including east Jerusalem	EMR	AMC92	100,620
Oman	EMR	COMMITTED	100,620
Pakistan	EMR	AMC92	10,358,010
Panama	AMR	COMMITTED	100,620

Participant name	WHO region	COVAX Participation model	Doses allocated Pfizer BioNTech – Comirnaty
Papua New Guinea	WPR	AMC92	100,620
Paraguay	AMR	COMMITTED	225,810
Peru	AMR	COMMITTED	329,940
Philippines	WPR	AMC92	100,620
Qatar	EMR	COMMITTED	100,620
Rwanda	AFR	AMC92	100,620
Sao Tome and Principe	AFR	AMC92	39,780
Senegal	AFR	AMC92	265,590
Sierra Leone	AFR	AMC92	287,820
Solomon Islands	WPR	AMC92	100,620
Somalia	EMR	AMC92	250,380
South Africa	AFR	COMMITTED	1,181,700
South Sudan	AFR	AMC92	482,040
Sri Lanka	SEAR	AMC92	100,620
Sudan	EMR	AMC92	1,274,130
Suriname	AMR	OPTIONAL	5,850
Tajikistan	EUR	AMC92	325,260
Timor-Leste	SEAR	AMC92	100,620
Togo	AFR	AMC92	100,620
Tunisia	EMR	AMC92	100,620
Uganda	AFR	AMC92	1,027,260
Ukraine	EUR	AMC92	100,620
United Republic of Tanzania	AFR	AMC92	3,724,110
Uzbekistan	EUR	AMC92	1,214,460
Viet Nam	WPR	AMC92	1,065,870
Yemen	EMR	AMC92	490,230
Zambia	AFR	AMC92	580,320
Zimbabwe	AFR	AMC92	774,540

* There are two additional participants for a total of 2,949,570 doses, where technical and legal issues will need to be worked out.

Table 2. Descriptive Statistics Summary of the Participants, Their Allocation and Total Coverage

Total Participants 99		AMC92 participants 71.7%		Optional purchase 6.1%		Committed purchase 22.2%		Coverage for round 1.2%
Participation Model	Round Average	Round Max	Round Min	Average	Max	Min		
AMC92 participants	1.71	9.08	0.05	6.4	20.04	3.71		
Optional purchase	0.83	1.52	0	6.33	18.66	1.01		
Committed purchase	1.9	7.35	0.5	7.59	20.12	3.72		
OVERALL	1.7	9.08	0	6.66	20.12	1.01		

Top product percent	Top natural percent	Top historical product percent	Top impartial product percent
100	100	100	100

Total Equity 0.0009	Preference 0	Unique Product 0
------------------------	-----------------	---------------------

Figure 1. Overview of the Total Round 5 Allocation (Only Participants Receiving Allocations*)

* There are two additional participants for a total of 2,949,570 doses, where technical and legal issues will need to be worked out.




Figure 2. Overview of the Total Round 5 Allocation on top of Previous Allocations (Only Participants with Allocations This Round)*

* There are two additional participants for a total of 2,949,570 doses, where technical and legal issues will need to be worked out.





Figure 3. Overview of the Total Round 5 Allocation on top of Previous Allocations (All Participants with Allocations*)

* There are two additional participants for a total of 2,949,570 doses, where technical and legal issues will need to be worked out.



ANNEX 2. Past Allocations

Table 1. Allocations to Date

Allocation Round	Product Name	WHO EUL Date	Allocation Approval Date	Doses Allocated	Doses Allocated Adjusted for Supply Shortages and Redeployments	Description
COVAX-1	Pfizer BioNTech – Comirnaty	30 Dec 2021	29 Jan 2021	1,200,420	1,200,420	Pfizer Feb-Mar 2021
COVAX-2	AstraZeneca – Vaxzevria	15 Feb 2021	23 Feb 2021, IAVG	75,996,000	75,412,800	AZ and SII-AZ Jan-May 2021
COVAX-2	SII – Covishield	15 Feb 2021	23 Feb 2021, IAVG	161,472,000	29,790,600	AZ and SII-AZ Jan-May 2021
COVAX-3	Pfizer BioNTech – Comirnaty	30 Dec 2021	15Mar 2021, IAVG	14,109,030	14,109,030	Pfizer Apr-Jun 2021
COVAX-4	AstraZeneca – Vaxzevria	15 Feb 2021	8 June 2021	17,366,400	17,366,400	AZ to cover COVAX Round 2 SII shortage
Dose Donations	AstraZeneca – Vaxzevria	15 Feb 2021	7 May 2021 12 May 2021 19 May 2021 06 July 2021	13,152,000	13,152,000	Donations received and allocated to date
Dose Donations	Moderna – mRNA-1273	30 April 2021	06 July 2021	25,650,340	25,650,340	Donations received and allocated to date
Dose Donations	Pfizer BioNTech – Comirnaty	30 Dec 2021	06 July 2021	16,333,200	16,333,200	Donations received and allocated to date
Dose Donations	Janssen - Ad26.COV 2-S	12 March 2021	06 July 2021	17,906,400	17,906,400	Donations received and allocated to date
TOTALS				343,185,790	210,921,190	

Table 2. Aggregate List of Dose Donations to Date

Dose Donation Round	Donor	Product	Doses Donated
DS-1	France	AstraZeneca – Vaxzevria	105,600
DS-2	France	AstraZeneca – Vaxzevria	499,200
DS-3	New Zealand	AstraZeneca – Vaxzevria	211,200
DS-4	France	AstraZeneca – Vaxzevria	1,096,800
DS-5	United States of America	Moderna – mRNA-1273	25,650,340
DS-5	United States of America	Pfizer BioNTech – Comirnaty	16,333,200
DS-5	United States of America	Janssen - Ad26.COV 2-S	17,906,400
DS-6	Japan	AstraZeneca – Vaxzevria	11,239,200
TOTALS			73,041,940